Biotechnology company Nuclera has introduced an antibody screening service to enable quick access to high-quality proteins and advance AI-driven discovery.
“Antibodies are one of the most important classes of therapeutic molecules, yet antibody discovery remains inefficient, with many initially promising candidates failing during downstream validation,” said Nuclera cofounder and CEO Dr Michael Chen. “A key bottleneck is the cost of recombinant antibody expression and binding validation, which limits the generation of high-quality data, and is holding back the full potential of AI/ML discovery.
Traditional antibody secondary screening methods are often slow and fragmented, resulting in large amounts of resources being spent on non-binders. Nuclera’s antibody service will address the bottleneck that remains in experimentally validating large numbers of candidates.
The service will help researchers to identify the most appropriate antibody candidates to progress to costly mammalian expression and functional testing. It is designed to streamline the transition from antibody hit generation to lead selection.
“By helping teams focus on the most promising candidates before scale-up, we are taking an important step toward enabling more effective use of AI in antibody discovery,” said Chen.
By using 96-plex binary cell-free expression and binding assays, the service screens full-length antibody libraries in parallel. It then rapidly narrows large candidate sets to a focused subset of confirmed binders. Surface Plasmon Resonance is then performed on prioritised hits for binding kinetics.
As AI-driven approaches generate increasingly large antibody libraries, the need for rapid, cost-effective triage solutions has become key to converting these vast pools of potential candidates.
Last month, Nuclera launched its nanodisc panel to support screening and scale-up of G-protein coupled receptors (GPCRs).
